Insmed Inc (INSM)vsInvivyd Inc. (IVVD)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
IVVD
Invivyd Inc.
$1.43
-4.03%
HEALTHCARE · Cap: $482.20M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1112% more annual revenue ($606.42M vs $50.04M). INSM leads profitability with a -2.1% profit margin vs -119.6%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
IVVD
Hold38
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 41.2% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -67.9% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : IVVD
The strongest argument for IVVD centers on Revenue Growth. Revenue growth of 41.2% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : IVVD
The primary concerns for IVVD are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while IVVD is a hypergrowth play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
IVVD is growing revenue faster at 41.2% — sustainability is the question.
IVVD generates stronger free cash flow (-15M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 38/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Invivyd Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?